AUTHOR=Zhang Chaoyue , Lin Yangtao , Kuang Qianjin , Li Hongjin , Jiang Qilong , Yang Xiaojun 

TITLE=Case report: A highly active refractory myasthenia gravis with treatment of telitacicept combined with efgartigimod

JOURNAL=Frontiers in Immunology

VOLUME=15

YEAR=2024

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1400459

DOI=10.3389/fimmu.2024.1400459

ISSN=1664-3224

ABSTRACT=<p>There is always a lack of effective treatment for highly active refractory generalized myasthenia gravis (GMG). Recently, telitacicept combined with efgartigimod significantly reduces circulating B cells, plasma cells, and immunoglobulin G, which brings promising therapeutic strategies. We report a case of a 37-year-old female patient with refractory GMG, whose condition got significant improvement and control with this latest treatment after multiple unsuccessful therapies of immunosuppressants. The new combination deserves further attention in the therapeutic application of myasthenia gravis.</p>